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Background: Use of carbapenems is expected to increase with rising prevalence of multidrug-resistant
bacteria. Available literature indicates that the incidence of seizure with ertapenem use ranges from
0.2% to 0.5% in adults. However, anecdotal clinical experience suggests that the frequency of seizures in
frail geriatric patients could be higher.
Aim: We sought to estimate the rate of seizures with the use of ertapenem in older hospitalized patients
and to identify possible predisposing factors for their occurrence.
Methods:We performed a retrospective chart review for hospital episodes of patients who were admitted
to the department of geriatric medicine of an acute care hospital and received at least one dose of
ertapenem between October 2009 and September 2010.
Results: Chart reviews for 116 patients were conducted. The mean age of the study population was 82.9
years [standard deviation (SD) ¼ 8.1] and 69% of the patients were female. The mean number of
comorbidities was 8.6 (SD ¼ 3.7) and the mean number of assisted or dependent activities of daily living
out of 5 was 3.5 (SD ¼ 2.0). Seizures occurred in six (5.17%) hospitalized patients. The Naranjo Adverse
Drug Reaction Probability Scale revealed a causality relationship graded as “possible” in two episodes
and “probable” in the remaining four episodes. Patients who experienced seizures were signiﬁcantly
younger (mean age: 75.7 vs. 83.3 years, p ¼ 0.023) and had fewer comorbidities (5.5 vs. 8.8, p ¼ 0.033).
Seizure occurrence had statistically nonsigniﬁcant associations with a history of central nervous system
disorders and previous seizures.
Conclusion: We found a higher rate of seizures amongst older hospitalized patients who were using
ertapenem than reported in existing literature. Further studies should include a wider population of
older hospitalized patients and compare seizure incidence with the use of carbapenem alternatives.
Copyright  2012, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
Open access under CC BY-NC-ND license.LLC.1. Introduction
The rising incidence rates of extended spectrum b-lactamase
(ESBL) resistance amongst nosocomial microbial colonization and
infection, coupled with limited antibiotic options against these
ESBL producing organisms, and convenient once-daily dosing of
ertapenem,1,2 have led to a steady increase in the use of ertapenem
in acute care hospitals. However, carbapenems are potentially
neurotoxic compounds that have been associated with seizures.3e5
Seizures associated with carbapenem use is not thought to bel, 11 Jalan Tan Tock Seng,
eo).
linical Gerontology & Geriatrics. Pa class-related phenomenon. Rather, it is dependent on speciﬁc
molecules in individual compounds, which bind to and competi-
tively inhibit the gamma-aminobutyric acid receptor in the brain.3,6
Although seizures occurred in less than 2% of patients who received
imipenem and meropenem,7e14 data on seizures associated with
ertapenem use are scarce. At present, this serious adverse reaction
is considered to be an infrequent event.15
To date, 16 studies of adults receiving ertapenem have been
published.2,16e27 Of these, 14 are randomized controlled trials with
active comparator arms, while two included open-label experi-
ences in treating ventilator-associated pneumonia.28,29 Of the
nearly 3000 patients who received a single dose of 1 g or more of
ertapenem, only three drug-related seizures were reported.16,21,22
Several other case reports show an incidence rate of up to 0.5% in
adults.30e35 History of central nervous system (CNS) disorders,ublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
H.Y. Neo et al. / Journal of Clinical Gerontology & Geriatrics 4 (2013) 17e2118impaired creatinine clearance, and a history of seizures were
identiﬁed as possible predispositions. However, the frequency of
seizures in frail older hospitalized patients who received intrave-
nous ertapenem appears to be higher in our clinical practice.
The objectives of this study were to (1) evaluate the rate of
seizures with the use of ertapenem in older hospitalized patients,
(2) measure the mortality risk in relation to ertapenem-related
seizures, and (3) to investigate the relationship between the rate
of seizure occurrence with ertapenem administration and risk
factors identiﬁed a priori, including age, comorbidity, functional
disability, pre-existing CNS disorders, and a history of seizures.
2. Methods
2.1. Participants
This is a retrospective cohort study conducted at a 1000-bed
acute care hospital in Singapore. All patients who were admitted to
the department of geriatric medicine and given at least one dose of
intravenous ertapenem between October 1, 2009 and September
31, 2010 were enrolled.
Patients selected for inclusion in the study cohort were identi-
ﬁed using the hospital pharmacy dispensing database (iPharm).
Using the patients’ unique identiﬁcation card number, we identi-
ﬁed the patients and their speciﬁc admissions for which ertapenem
was administered and retrieved the relevant inpatient admission
notes for data collection from the hospital’s medical records ofﬁce.
Data collectionwas carried out fromDecember 2010 toMarch 2011.
Inpatient admission notes that were not available for review during
the data collection period were excluded from the study.
This study was initiated as part of a department’s internal audit
toward quality improvement. Approval was obtained from the
Head of Department, Geriatric Medicine, Tan Tock Seng Hospital.
2.2. Data collection
Based on literature review that yielded several case reports and
case series, a number of factors postulated to be associated with
increased predisposition to seizures with ertapenem use were
identiﬁed a priori, and their associationwith seizures was assessed.
These included age, comorbidity, functional disability, history of
CNS disorders, history of seizures, renal impairment (estimates of
creatinine clearance), and electrolyte abnormalities.
We reviewed the inpatient admission notes of all included
patients and collected demographic data such as age, gender,
ethnicity, and duration of hospital stay. Dosage and duration of
ertapenem administration were also obtained by reviewing the
inpatient admission notes and the electronic inpatient medication
records. Data on the risk factors identiﬁed a priori during literature
review, including age, number of diseases, functional disability in
terms of number of dependent or assisted activities of daily living
(ADLs), history of CNS disorders, history of seizures, renal impair-
ment (estimates of creatinine clearance), and electrolyte abnor-
malities were collected. Prognosticating measures such as age,
comorbidity, and functional disability aid in indicating complex
needs and, perhaps, frailty in the study population. In instances
where patients were admitted two or more times during the study
period, only data from the earliest admission are analyzed.
2.3. Identiﬁcation and description of seizures
The primary study outcome was deﬁned as occurrence of
seizures during the period of hospitalization after the administra-
tion of ertapenem. Seizures were considered to be possibly related
to ertapenem use if it occurred after at least one dose of ertapenemwas administered. By reviewing inpatient charts, evidence of
seizure activity including information on the phenotypic presen-
tation, frequency, and timing of seizures, as well as the presence or
absence of an electroencephalogram was collected. In-hospital
mortality information was also collected as a secondary outcome
using chart review.
In order to evaluate the strength of the causality relationship
between ertapenem use and seizure occurrence, the Naranjo
Adverse Drug Reaction Probability Scale (NADRPS)36,37 was applied
to all identiﬁed seizures events that occurred after ertapenem
administration. This is an objective ten-item weighted scale that
has gained wide applicability in establishing causality relationship
between administered drugs and adverse events. Probability is
assigned as deﬁnite, probable, possible, or doubtful on the basis of
the score obtained. Previous case studies and case series examining
ertapenem-related seizures have also used NADRPS as a measure of
causality.30e35
2.4. Statistical analyses
All data analyses were performed using IBM SPSS Statistics
version 19. Two-sided p values less than 0.05 were taken to indicate
statistical signiﬁcance. Demographic features of the study pop-
ulation were described. The proportion of patients who had
seizures after ertapenem administration was determined. The
independent t test and the Chi-square test were used to analyze
possible associations between seizures and continuous and cate-
gorical variables, respectively. These include age, gender, number of
comorbidities, pill burden, history of CNS disorders, history of
seizures, renal impairment (estimates of creatinine clearance), and
electrolytic abnormalities. The KruskaleWallis test was used for
analyzing the median length of hospital stay and the Fisher exact
test was used for analyzing the in-hospital mortality in view of
expected low mortality.
3. Results
A total of 118 patients met the inclusion criteria and were
therefore included in the study. The charts of two patients were
unavailable for examination, and thus they were excluded from
analyses.
The mean age was 82.9 years [standard deviation (SD) ¼ 8.1].
Majority of the participants were women (62%). The mean number
of comorbidities per patient was 8.6 (SD ¼ 3.7), while the mean
number of assisted or dependent ADLs was 3.5 (SD ¼ 2.0) (Table 1).
For 66.7% of hospital episodes, ertapenem was prescribed for
urinary tract infections, as well as for bacteremia in 11.6% of the
episodes. In the remaining 21.7% it was prescribed for various
combinations of urinary tract infection, bacteremia, and other
concurrent infections.
Seizures occurred in six (5.17%) of the 116 hospitalized patients.
All seizures were clinically diagnosed focal or generalized tonice
clonic convulsions. With the exception of one case where the
seizure occurred on the 2nd day of ertapenem administration, all
the other patients had seizures on or after the 4th day of antibiotic
administration. Recurrent seizures were seen in three patients.
Characteristics of these patients and their seizures are summarized
in Table 2. By applying the NADRPS to these six seizure episodes,
we found a causality relationship graded as “possible” in two
patients with seizures and “probable” in the other four (Table 3).
Two patients with seizures passed away during the same period
of admission. One passed away on the day of seizure onset, while
the other passed away 4 days after seizure onset. The cause of death
of the ﬁrst patient was attributed to urinary tract infection and
pneumonia, while that of the second patient was reported as sacral
Table 1
Baseline characteristics of the study population.
Study population
(n ¼ 116)
Seizure (n ¼ 6) No seizure
(n ¼ 110)
p (for differences between seizure
and nonseizure groups)
Mean age, years (SD) 82.9 (8.1) 75.7 (4.5) 83.3 (8.3) 0.023
Female gender, n (%) 80 (69) 4 (66.6) 76 (69.0) 0.607
Ethnicity, n (%)
Chinese 105 (90.5) 4 (66.7) 101 (91.8)
Malay 6 (5.2) 1 (16.7) 5 (4.5)
Indian 4 (3.4) 0 (0) 4 (3.6) d
Others 1 (0.8) 1 (16.7) 0 (0)
Mean number of assisted or dependant ADLs, n (SD) 3.5 (2.0) 3.8 (1.9) 3.5 (2.1) 0.692
Mean number of medications, n (SD) 7.8 (3.6) 6.0 (4.0) 7.9 (3.5) 0.215
Mean number of comorbid conditions, n (SD) 8.6 (3.7) 5.5 (2.1) 8.8 (3.7) 0.033
History of seizures, n (%) 6 (5.2) 1 (16.7) 5 (4.5) 0.278
Use of antiepileptic agents, n (%) 15 (12.9%) 1 (16.7) 14 (12.7) 0.573
History of CNS disease, n (%) 95 (81.9) 6 (100) 89 (80.9) 0.293
Median length of hospital stay, days (IQR) 21 (13e37) 40 (20e47) 21 (13e35) 0.157
In-hospital death, n (%) 12 (10.3) 2 (33.3) 10 (9.1) 0.117
ADLs ¼ activities of daily living; CNS ¼ central nervous system; IQR ¼ interquartile range; SD ¼ standard deviation.
p value less than 0.05 are in bold to highlight statistical signiﬁcance.
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was higher in the seizure group than in the nonseizure group
(33.3% vs. 9.1%; relative risk ¼ 3.66), although this was not statis-
tically signiﬁcant.
Patients in the seizure group were signiﬁcantly younger (mean
age: 75.7 vs. 83.3 years, p¼ 0.023) and had fewer comorbidities (5.5
vs. 8.8, p ¼ 0.033), compared with those without seizures. All
patients in the seizure group had a history of CNS disorders such as
cerebral gliosis, previous cerebrovascular thrombosis, and hemor-
rhage, compared with 80.9% among those without seizures. The
high rate of CNS disorders amongst these elderly patients is largely
accounted for by the presence of lacunar infarcts and micro-
hemorrhages noted on previous neuroimaging studies. A higher
proportion of patients with seizures had a history of antiepileptic
drug use and seizures before admission than those without
seizures, although these differences did not reach statistically
signiﬁcant levels (Table 1).
4. Discussion
To the best of our knowledge, this is the ﬁrst retrospective
cohort study investigating the relationship between ertapenem
use and seizures in the elderly, many of whom are more complex
and may be frail. In previous researches on seizures and ertape-
nem use that included several case reports and one case series,
seizure incidence was reported to be between 0.2% and 0.5%
among adults.30e35 A manufacturer review of the inﬂuence of age
(>65 vs. <65 years) on the occurrence of adverse drug events didTable 2
Characteristics of patients with seizures and concurrent ertapenem use.
Patient no. 1 2 3
Gender, age in years F, 75 F, 68 F,
Indication for
ertapenem use
ESBL þ Klebsiella UTI ESBL þ Escherichia coli UTI,
sacral sore, pneumonia
ES
co
History of CNS disorder Yes, ischemic stroke Yes, ischemic stroke, gliosis Ye
tu
History of seizure Nil Nil N
Use of AED Nil Nil N
Creatinine (mmol/L) 100 41 39
In-hospital death No Yes N
Type of seizures Focal X1, GTC X1 Facial twitching GT
Number of days
until seizures
2 (second episode
on Day 10)
13 5
AED ¼ anti-epileptic drug; CNS ¼ central nervous system; ESBLþ ¼ extended spectrum b
infection.not identify age-related differences in seizure rates.38,39 Pharma-
cokinetic analysis of ertapenem use in elderly patients demon-
strated only mild, nonsigniﬁcant increases in area under the
concentrationetime curve and decreases in clearance compared
with those parameters in healthy adult volunteers, with no need
for dosage adjustment.40,41
However, our ﬁndings indicate that the rates of seizures with
the use of ertapenem in older hospitalized patients whowere likely
to be frail far exceeded what was previously reported in adults
(5.17% vs. 0.5%). The true risk of seizures may even be higher given
that from anecdotal observations, attending physicians tended to
avoid prescribing ertapenem in older patients deemed to be at
higher risk of seizures.
Of the six patients who were identiﬁed with seizure episodes,
four were classiﬁed as having “probable” and two having “possible”
causality relationship with ertapenem use (NADRPS score range:
3e7). This magnitude of causal association is comparable if not
superior to existing case series and case reports (NADRPS score
range: 3e5).
Our study revealed a higher hospital mortality amongst patients
with ertapenem-related seizures (33.3% vs. 9.1%, p ¼ 0.117), although
this difference in mortality was not statistically signiﬁcant given the
small number of patients admitted with seizure episodes. Although
seizures may increase mortality risk due to the elevated risks of cere-
bral insults, hypoxemia, and aspiration pneumonia, it is quite possible
that the higher mortality observed could also reﬂect concurrent and
severe illness associated with both seizure occurrence and death.
Because of the retrospective design of this study, we are unable to4 5 6
81 M, 75 F, 79 M, 76
BL þ E.
li UTI
ESBL þ E. coli
bacteremia
ESBL þ E. coli
bacteremia
ESBL þ E. coli UTI
s, brain
mor
Yes, gliosis, ischemic
stroke,
encephalomalacia
Yes, ischemic stroke Yes, ischemic stroke
il Yes Nil Nil
il Phenytoin Nil Nil
49 111 94
o No Yes No
C X1 Focal X2 GTC X4 GTC X1
11 (second episode
on Day 13)
10 (four episodes
on Day 10)
5
-lactamase producing; GTC ¼ generalized toniceclonic seizures; UTI ¼ urinary tract
Table 3
Application of the Naranjo Adverse Drug Reaction Probability Scale to patients with seizures.
Question Score assigned to answer
Y N Do not know
Patient with seizure 1 2 3 4 5 6
Are there previous conclusive reports on this reaction? þ1 0 0 þ1 þ1 þ1 þ1 þ1 þ1
Did the adverse event occur after the suspected drug was administered? þ2 1 0 þ2 þ2 þ2 þ2 þ2 þ2
Did the adverse reaction improve when the drug was discontinued or
a speciﬁc antagonist was administered?
þ1 0 0 0 þ1 þ1 þ1 0 þ1
Did the adverse reaction reappear when the drug was readministered? þ2 1 0 þ2 1 0 þ2 0 1
Are there alternative causes (other than the drug) that could have
on their own caused the reaction?
1 þ2 0 1 1 þ2 1 1 þ2
Did the reaction reappear when a placebo was given? 1 þ1 0 0 0 0 0 0 0
Was the drug level detected in the blood (or other ﬂuids) in
concentrations known to be toxic?
þ1 0 0 0 0 0 0 0 0
Was the reaction more severe when the dose was increased
or less severe when the dose was decreased?
þ1 0 0 0 0 0 0 0 0
Did the patient have a similar reaction to the same or similar
drugs in any previous exposure?
þ1 0 0 0 0 0 0 0 0
Was the adverse event conﬁrmed by any objective evidence? þ1 0 0 þ1 þ1 þ1 þ1 þ1 þ1
Total Score 5 3 7 6 3 6
Score >9 ¼ deﬁnite relationship; score 5e8 ¼ probable relationship; score 1e4 ¼ possible relationship; score 0 ¼ doubtful relationship.
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enable adjustment for the inﬂuenceofdiseaseseverityonmortality.As
such, despite the positive association with mortality in our study, we
are unable to draw a deﬁnitive conclusion that ertapenem-related
seizures lead to increased mortality. Future prospective studies with
large sample sizes where disease severity is measured as a confound-
ing variable would be helpful to ascertain this issue.
One might have expected that age and comorbidity burden
would be associated with the risks of ertapenem-induced seizures.
However, the opposite was observed in our study population. The
reason for this surprising ﬁnding is not clear from our data. Because
of the retrospective study design, data on speciﬁc risk factors for
seizures identiﬁed a priori, such as electrolyte abnormalities and
creatinine clearance, were not available due to incomplete docu-
mentation or testing. Incomplete data collection on creatinine
clearance further precluded the analysis of appropriate drug dosing
with the rates of seizure occurrence.
Similarly, plasma antiepileptic drug levels, as well as changes in
dosing regimen of these drugs during the course of antibiotic
administration, could not be evaluated. Lack of this set of important
information and the small number of seizure events precluded the
performance of meaningful regression analyses to address poten-
tial confounding variables. Nevertheless, we postulate that physi-
cians may have tended to prescribe ertapenem less cautiously in
younger patients, patients with less comorbidity, and others who
were considered to be at lower risk for adverse events. Further and
larger studies are needed to examine the relationship between
seizures and these risk factors more closely.
We acknowledge that the limitations of this study include its
relatively small sample size, the absence of a comparison group not
exposed to ertapenem, and unavailability of data on several
important variables as discussed. The study population is conﬁned
to the more complex hospitalized older patients typically seen in
geriatric medicine departments. Therefore, our results cannot be
extrapolated to younger and less complex patients. Furthermore, as
geriatricians may have avoided the use of carbapenems in patients
who were more frail and sick, and thus deemed to be at higher
seizure risk, this may have undermined our attempt to estimate the
true risk of ertapenem-induced seizures in older patients. Never-
theless, this study contributes to the literature by highlighting the
higher seizure incidence amongst older and more complex hospi-
talized patients who received ertapenem, and thus sets the stage
for future studies to be performed over a wider patient spectrum
and across different carbapenems.5. Conclusion
We have found that the rates of seizures with the use of erta-
penem in older and more complex hospitalized patients far
exceeded those previously reported in adults. It is likely that the use
of ertapenem lowers the seizure threshold in elderly patients with
predisposing risk factors. Usage of carbapenems is expected to
increase with the rising prevalence of multiresistant bacteria.
Therefore, it is important for clinicians to be aware that older
patients may be more susceptible to this potentially neurotoxic
adverse effect of ertapenem and exercise due vigilance and care
when prescribing this antibiotic.References
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